{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000062","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.265962+00:00","generated_at":"2026-06-15T10:04:46.746647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio reports Q1 net loss $18.7M; cash $76.1M; SENTI-202 IND on track for 2H 2023","bullets":["Net loss of $18.7M ($0.42 per share) vs $11.8M loss in Q1 2022; revenue $1.3M.","Cash, equivalents & short-term investments $76.1M; cash runway expected through at least Q1 2024.","R&D expense $11.3M (+49% YoY) from increased headcount for preclinical programs.","SENTI-202 logic-gated CAR-NK on track for IND filing in 2H 2023; new AACR data shown.","Technology transfer to Alameda cGMP facility started to support clinical-scale manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000062","json":"https://secwatch.observer/filing/0001854270-23-000062.json","markdown":"https://secwatch.observer/filing/0001854270-23-000062.md","text":"https://secwatch.observer/filing/0001854270-23-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/0001854270-23-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/snti-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T10:04:46.746647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb84d5f9f4fefc7fdbb7488ba8cd3a88a22b75e6","claim":"Senti Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $18.7 million, EPS $0.42 per basic and diluted share.","evidence_excerpt":"Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/0001854270-23-000062-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$18.7 million"},{"label":"EPS","value":"$0.42 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}